NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx℠ Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx℠ Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx℠) Tech and ATP Programs

The RADx Tech and ATP programs are supporting late-stage development of innovative point-of-care, home-based tests, and clinical laboratory tests.

Summary data on proposals submitted to the RADx℠ Tech and ATP Programs.

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

NIBIB’s Dr. Kaitlyn Sadtler is a study lead and Principal Investigator working with NIH colleagues to test people who were infected with SARS-CoV-2 and developed antibodies but did not develop symptoms. Read more about the study.

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about the project.


View videos about RADx Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADxSM Tech/ATP programmatic or technical inquiries:

All other RADxSM Tech/ATP Applicants:

SBIR/STTR Applicants:

All others:

Related News

April 6, 2021
epidermal patch attached to forearm to monitor blood pressure and metabolites
NIBIB-funded engineers have developed a flexible epidermal patch that can simultaneously and continuously monitor cardiac output and metabolic levels of glucose, lactate, caffeine, or alcohol. The patch is a major step towards continuous non-invasive health monitoring.
March 31, 2021
woman looking at home covid19 test
The CDC, in collaboration with the NIH, has launched an innovative community health initiative called “Say Yes! COVID Test.” Up to 160,000 residents in two US communities will have access to free, rapid antigen tests that they can administer themselves to use three times a week for one month.
March 23, 2021
COVID19 testing technology with digital health app for smartphone
NIH has awarded four additional contracts for the development and scaled-up manufacturing of new COVID-19 diagnostic testing technologies through its Rapid Acceleration of Diagnostics Tech (RADx) initiative. The awards total $29.3 million and will help increase testing capacity for COVID-19.
March 23, 2021
ROSALIND, a software leader in extracting meaningful insights from diverse pools of life science data, today announced the launch of a web-based platform for monitoring the emergence of SARS-CoV-2 variants and evaluating the effects on the performance of diagnostic tests. The new platform, called the ROSALIND Diagnostic Monitoring (DxM) system, is available starting today and will be used by diagnostic test manufacturers and regulators to monitor assay performance against the rapidly evolving SARS-CoV-2 variants. Source: Business Wire.
March 1, 2021
diagnostic test in a box
An NIH-funded research team has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home COVID-19 Test, which received FDA emergency use authorization for use with a prescription.